Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Endologix Inc (ELGX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 383,036
  • Shares Outstanding, K 83,450
  • Annual Sales, $ 192,930 K
  • Annual Income, $ -154,680 K
  • 36-Month Beta 0.72
  • Price/Sales 2.07
  • Price/Cash Flow N/A
  • Price/Book 4.49
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.61
  • Most Recent Earnings -0.17 on 11/07/17
  • Next Earnings Date 02/28/18
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

    Medical - Dental Suppliers

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.42 +3.78%
on 01/09/18
5.71 -19.61%
on 12/13/17
-1.10 (-19.33%)
since 12/12/17
3-Month
4.42 +3.78%
on 01/09/18
6.28 -26.85%
on 11/06/17
-0.57 (-11.05%)
since 10/12/17
52-Week
4.08 +12.50%
on 08/07/17
7.66 -40.08%
on 05/01/17
-1.86 (-28.84%)
since 01/12/17

Most Recent Stories

More News
Endologix, Inc. to Present at the J.P. Morgan Healthcare Conference

Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John McDermott, Chief Executive Officer, and Vaseem Mahboob, Chief...

JPM : 113.42 (+0.67%)
ELGX : 4.59 (-0.65%)
Factors of Influence in 2018, Key Indicators and Opportunity within Endologix, Haemonetics, Prudential Financial, AdvanSix, PolyOne, and Rexford Industrial Realty -- New Research Emphasizes Economic Growth

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Endologix, Inc. (NASDAQ:ELGX),...

PRU : 124.10 (-0.02%)
ELGX : 4.59 (-0.65%)
REXR : 28.38 (-0.25%)
POL : 45.65 (-1.25%)
HAE : 64.12 (-0.99%)
ASIX : 43.81 (+1.53%)
ENDOLOGIX INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Endologix, Inc. - ELGX

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Endologix, Inc. (NasdaqGS:...

ELGX : 4.59 (-0.65%)
ENDOLOGIX INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Endologix, Inc. - ELGX

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Endologix,...

ELGX : 4.59 (-0.65%)
Breakfast Technical Briefing on Medical Supplies Stocks -- Endologix, Dextera Surgical, Becton, Dickinson, and Ekso Bionics

If you want a Stock Review on ELGX, DXTR, BDX, or EKSO then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. DailyStockTracker.com has issued research reports...

DXTR : 0.0399 (-0.25%)
EKSO : 2.05 (+1.99%)
BDX : 227.71 (+0.84%)
ELGX : 4.59 (-0.65%)
Endologix, Inc. to Present at the Piper Jaffray 29th Annual Healthcare Conference

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John McDermott, Chief Executive Officer, will present at the Piper...

ELGX : 4.59 (-0.65%)
Endologix Reports Third Quarter 2017 Financial Results

Endologix, Inc. (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the third quarter ended September 30, 2017.

ELGX : 4.59 (-0.65%)
Endologix, Inc. to Present at the Stifel 2017 Healthcare Conference

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that John McDermott, Chief Executive Officer, and Vaseem Mahboob, Chief...

ELGX : 4.59 (-0.65%)
Endologix Appoints John Onopchenko as Chief Operating Officer

Endologix, Inc. (Nasdaq:ELGX), a developer and marketer of innovative treatments for aortic disorders, announced today that it has appointed John Onopchenko as the Company's Chief Operating...

ELGX : 4.59 (-0.65%)
Endologix, Inc. to Announce Third Quarter 2017 Financial Results on November 7, 2017

Endologix, Inc. (Nasdaq: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced that it will report financial results for the third quarter of fiscal...

ELGX : 4.59 (-0.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators mostly agree with the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More

Business Summary

Endologix, Inc. develops, manufactures and markets products for the treatment of coronary and vascular diseases. A leader in the emerging field of vascular brachytherapy, Endologix, has developed a unique method for the delivery of radiation to prevent restenosis following the interventional treatment...

See More

Key Turning Points

2nd Resistance Point 4.70
1st Resistance Point 4.65
Last Price 4.59
1st Support Level 4.54
2nd Support Level 4.48

See More

52-Week High 7.66
Fibonacci 61.8% 6.29
Fibonacci 50% 5.87
Fibonacci 38.2% 5.45
Last Price 4.59
52-Week Low 4.08

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.